MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs

Shuo Chen¹
Jin-Wen Jiao²
Kai-Xuan Sun¹
Zhi-Hong Zong³
Yang Zhao¹

¹Department of Gynecology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China; ²Department of Gynecology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, People's Republic of China; ³Department of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang, People's Republic of China

Background: Accumulating studies reveal that aberrant microRNA (miRNA) expression can affect the development of chemotherapy drug resistance by modulating the expression of relevant target proteins. The aim of this study was to investigate the role of miR-133b in the development of drug resistance in ovarian cancer cells.

Methods: We examined the levels of miR-133b expression in ovarian carcinoma tissues and the human ovarian carcinoma cell lines (A2780, A2780/DDP and A2780/Taxol, respectively). We determined the cell viability of these cell lines treated with cisplatin or paclitaxel in the presence or absence of miR-133b or anti-miR-133b transfection using the MTT assay. Reverse transcription polymerase chain reaction and Western blotting were used to assess the mRNA and protein expression levels of two drug-resistance-related genes: glutathione S-transferase (GST)- π and multidrug resistance protein 1 (MDR1). The dual-luciferase reporter assay was used to detect the promoter activity of GST- π in the presence and absence of miR-133b.

Results: The expression of miR-133b was significantly lower in primary resistant ovarian carcinomas than in the chemotherapy-sensitive carcinomas ($P < 0.05$), and the same results were found in primary resistant ovarian cell lines (A2780/Taxol and A2780/DDP) compared to the chemotherapy-sensitive cell line (A2780; $P < 0.05$). Following miR-133b transfection, four cell lines showed increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection reduced cell sensitivity to paclitaxel and cisplatin. Dual-luciferase reporter assay showed that miR-133b interacted with the 3'-untranslated region of GST- π . Compared to controls, the mRNA and protein levels of MDR1 and GST- π were downregulated after miR-133b transfection and upregulated after anti-miR-133b transfection.

Conclusion: MicroRNA-133b may reduce ovarian cancer drug resistance by silencing the expression of the drug-resistance-related proteins, GST- π and MDR1. In future, the combination of miR-133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers.

Keywords: cisplatin, drug resistance, ovarian cancer cells, paclitaxel

Introduction

Epithelial ovarian cancer is the leading cause of death from gynecological cancers worldwide, and is the fifth leading cause of cancer death in women.¹ The 5-year survival rate for all stages of ovarian cancer has been estimated to be 45.6%.² Primary treatment of epithelial ovarian cancer is surgical resection of visible disease, followed by adjuvant chemotherapy. Conventional chemotherapy drugs, such as cisplatin and paclitaxel, have long-term clinical application in many cancers, including ovarian cancer.³ Unfortunately, numerous ovarian cancer patients who initially respond to

Correspondence: Yang Zhao
155 North of Nanjing Street, Heping District, Shenyang City, Liaoning Province, People's Republic of China
Tel +86 139 4014 0056
Email yida.zhaoyang@163.com

cisplatin or paclitaxel therapy become drug resistant and relapse. Therefore, the identification of new biomarkers, treatments, and therapeutic targets for human epithelial ovarian cancer is required.

MicroRNAs (miRNAs) are promising diagnostic and prognostic molecular biomarkers in cancer.^{4,5} They are endogenous, noncoding RNAs that silence gene expression by inhibiting mRNA stability or translation, and frequently target the 3'-untranslated regions (3'-UTRs).⁶ Typically, miRNAs function in a variety of cellular events (eg, proliferation, differentiation, and apoptosis) and have been implicated in tumorigenesis.⁷⁻⁹ In recent years, more attention has been paid to the role of miRNAs in drug resistance, with accumulating evidence that aberrant miRNA expression can affect drug resistance by modulating the expression of relevant target proteins, including drug transporters, cell apoptosis mediators, and cell-cycle-related components.¹⁰ For example, miR-27a,¹¹ miR-106a,¹² and miR-487¹³ have been implicated in the development of drug resistance by regulating gene expression of a number of different target genes.

In this study, we examined the role of miR-133b in drug resistance. miR-133b modulates cell proliferation, cell apoptosis, cell migration, and invasion, and is downregulated in gastric,¹⁴ bladder,¹⁵ and colon¹⁶ cancers. Guo et al showed that miR-133b has a tumor suppressor role in gastric cancer; it decreases fascin actin-bundling protein 1 expression, a protein that increases cell motility and cancer metastasis.¹⁴ Similarly, Chen et al reported that miR-133b decreases bladder cancer cell proliferation and apoptosis by reducing expression of Bcl-w and Akt1.¹⁵ On the other hand, Qin et al reported that miR-133b acts as an oncogene in cervical cancer, and promotes carcinoma development by activating the ERK and AKT1 signaling pathways.¹⁷ Therefore, miR-133b may play multiple roles in cancer proliferation and metastasis.

Despite the importance of miR-133b in tumorigenesis and the potential function of miRNAs in drug resistance, there are no studies investigating the role of miR-133b in drug-resistant human epithelial ovarian cancer cells to date. In this study, we investigated whether miR-133b is involved in the development of cisplatin and paclitaxel drug resistance in an ovarian cancer cell line.

Materials and methods

Cell culture

The serous cystic adenocarcinoma ovarian cell line A2780 and the paclitaxel-resistant A2780 (A2780/Taxol) cell line were kindly given to us by Dr Biao Wang (College of Basic Medical Sciences, China Medical University, Shenyang,

People's Republic of China). The cisplatin-resistant A2780 (A2780/DDP) cell line was purchased from the China Center for Type Culture Collection (Shanghai, People's Republic of China), and the OVCAR3 cell line was purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were maintained in RPMI 1640 (A2780/DDP, A2780/Taxol, OVCAR3) or Dulbecco's Modified Eagle's Medium (A2780) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin. Cell lines were kept in a humidified atmosphere of 5% CO₂ at 37°C with or without cisplatin (0, 37.5, 150, 600, 2,400, and 9,600 ng/mL) or paclitaxel (0, 6.25, 25, 100, 400, and 1,600 ng/mL) treatment. Transfection with 50 nM miR-133b, anti-miR-133b (Biomics Biotech, Jiangsu, People's Republic of China), or a scrambled miRNA sequence (miR-C, Anti-C) was performed using the Lipofectamine 2000 in accordance with the manufacturer's guidelines (Thermo Fisher Scientific, Waltham, MA, USA). The sequences were as follows: miR-133b, 5'-UUU GGU CCC CUU CAA CCA GCU A-3'; miR-C, 5'-UUC UCC GAA CGU GUC ACG UTT-3'; anti-miR-133b, 5'-UAG CUG GUU GAA GGG GAC CAA A-3'; and anti-C, 5'-CAG UAC UUU UGU GUA GUA CAA A-3'. No ethics statement was required from the institutional review board for the use of these cell lines.

Ovarian carcinoma specimens

Forty-four ovarian carcinomas were collected from patients who underwent surgical resection at the Department of Gynecology of the First Affiliated Hospital of China Medical University (Shenyang, Liaoning, People's Republic of China). The tumor specimens were independently confirmed by two pathologists. Samples were frozen immediately in liquid nitrogen and stored at -80°C until use. None of the patients had preoperative chemotherapy or radiotherapy. Informed consent was obtained from all subjects, the study was approved by the China Medical University Ethics Committee, and all specimens were handled and made anonymous according to ethical and legal standards.

Cell viability assay

MTT assay using the tetrazolium 3-(4,5)-dimethylthiazoliazolide (-z-y1)-3,5-di-phenyltetrazolium bromide dye (Beyotime, Jiangsu, People's Republic of China) was employed to determine cell viability. Briefly, approximately 2.5×10³ cells/well were seeded into a 96-well plate and allowed to adhere overnight. At 0, 24, 48, and 72 hours, 20 µL of MTT solution was added into each well of the plate, and the plates were subsequently incubated for 4 hours in the incubator.

Then, the liquid was removed from the plate, and 150 μ L of dimethyl sulfoxide was added to each well. The plate was measured at 490 nm.

Dual-luciferase reporter assay

The miR-133b binding site in glutathione S-transferase (GST)- π , which is abundantly expressed in cancer cells, was predicted using a web-based miRNA program (<http://www.microrna.org>). The target sequence of the wild-type 3'-UTR of GST- π was cloned into a luciferase vector containing the Renilla luciferase gene. In addition, a mutant 3'-UTR of GST- π was cloned by Genethem (Shanghai Genechem Co., Ltd, Shanghai, People's Republic of China). HEK-293T cells and A2780 cells were cotransfected with miR-C or miR-133b using Lipofectamine 2000 (Thermo Fisher Scientific). Cells were collected 48 hours after transfection and analyzed using the Dual-Luciferase Reporter Assay System (Promega Corporation, Fitchburg, WI, USA). Luciferase activity values were normalized relative to that of the Renilla luciferase internal control. Each reporter plasmid was transfected at least three times, and each sample was assayed in triplicate. The wild sequence for GST- π (NM_000852) 3' UTR was: GGGTTGGGGGGACTCTGAGCGGGAGGCAGAGTTTGCCTTCCTTTCTCCAGGACCAATAAAATTTCTAAGAGAGCT; while mutant sequence was GGGTTGGGGGGACTCTGAGCGGGAGGCAGAGTTTGCCTTCCTTTCTCCATCGGTCTG TAAAATTTCTAAGAGAGCT.

Real-time reverse transcription polymerase chain reaction

Total RNA was extracted from the ovarian carcinoma cell lines using TRIzol[®] (Takara, Kyoto, Japan). Real-time reverse transcription (RT) polymerase chain reaction (PCR) was performed from 2 μ g of total RNA using avian myeloblastosis virus reverse transcriptase and random primers (Takara). PCR primers were designed according to the sequences in GenBank (Table S1). Amplification of cDNA was performed according to the manufacturer's protocol using an SYBR Premix Ex Taq II kit (Takara). All the PCR experiments were accompanied with a no-template control and 18S as an internal control. The relative gene expression level (the amount of target gene normalized to the endogenous control gene) was calculated using the comparative CT method: $2^{-\Delta\Delta C_t}$.

Western blot analysis

Protein quantification was performed according to the Bradford method using the Bio-Rad protein assay kit

(Bio-Rad Laboratories Inc., Hercules, CA, USA). A total of 40 μ g of denatured proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 12% acrylamide gels, and then transferred to Hybond[™] membranes (Amersham Biosciences, Freiburg, Germany). The membranes were blocked overnight in 5% skim milk in Tris-buffered saline with Tween 20. For immunoblotting, the membranes were incubated at 4°C overnight with the multidrug resistance 1 (MDR1) antibody (1:500; Bioss, Peking, People's Republic of China) and the GST- π antibody (1:500; Proteintech Group, Chicago, USA). Then, they were rinsed with Tris-buffered saline with Tween 20 and incubated with the anti-rabbit IgG antibodies conjugated to horseradish peroxidase (Dako, Carpinteria CA, USA) at a dilution of 1:5,000. After applying electrochemiluminescent plus detection reagents (Santa Cruz Biotechnology Inc., Dallas, TX, USA), the protein bands were visualized using an X-ray film (Fujifilm, Tokyo, Japan). The immunoblots were washed with Western blot stripping buffer (pH 2–3; Nacalai, Tokyo, Japan) and probed using a monoclonal antibody specific for glyceraldehyde-3-phosphate (1:2,000; Proteintech Group).

Statistical analysis

Statistical evaluation was performed using the Student's *t*-test to differentiate the means of different groups. A *P*-value of <0.05 was considered statistically significant. SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was employed to analyze all data.

Results

miR-133b expression is lower in drug resistant ovarian carcinomas and cell lines

miR-133b expression was significantly lower in primary resistant ovarian carcinomas compared to the chemotherapy-sensitive carcinomas (Figure 1A and B, *P*<0.05). miR-133b expression was significantly lower in primary resistant ovarian cell lines (A2780/Taxol and A2780/DDP) compared to the chemotherapy sensitive (A2780) cell line (Figure 1C, *P*<0.05).

miR-133b transfection increases the sensitivity of ovarian carcinoma cell lines to chemotherapy drugs

Following miR-133b transfection, the sensitivity of A2780 cells to cisplatin was increased compared with negative control cells or miR-C cells; however, anti-miR-133b transfection decreased the sensitivity to cisplatin (Figure 2A,

Figure 1 MiR-133b expression is lower in drug-resistant ovarian carcinomas and cell lines.

Notes: (A and B) miR-133b expression was significantly lower in primary resistant ovarian carcinomas compared to the chemotherapy-sensitive carcinomas. (C) Comparison of miR-133b expression relative to 18S expression in the nonresistant ovarian cancer cell line (A2780), the cisplatin-resistant ovarian cell line (A2780/DDP), and the paclitaxel-resistant ovarian cell line (A2780/Taxol) determined by reverse transcription polymerase chain reaction. Data are expressed as the mean $\pm$ standard deviation; * $P < 0.05$.

$P < 0.05$). Similar results were observed with the A2780/DDP, A2780/Taxol, and OVCAR3 cells lines. The sensitivity to paclitaxel was also increased after miR-133b transfection, while it was decreased after anti-miR-133b transfection in all cell lines (Figure 2B, $P < 0.05$). Details can be found in Table S2.

Predicted binding region and transcriptional effects of miR-133b on its target gene, GST- π

To gain a greater understanding of the role of miR-133b in the drug resistance of human ovarian cancer, we looked for its potential downstream targets using a web-based

miRNA program (<http://www.microrna.org>). Based on the predicted binding region of miR-133b in the 3'-UTR of GST- π , we propose that GST- π is a direct target of miR-133b (Figure 3A). Furthermore, using the dual-luciferase reporter assay, we found that miR-133b significantly decreased the luciferase activity of the GST- π 3'-UTR in both HEK-293 T and A2780 cells (Figure 3B, $P < 0.05$ for both), but not mutant sequences of the 3'-UTR of GST- π . These results indicate that miR-133b directly binds to the 3'-UTR of wild type GST- π .

miR-133b downregulates MDR1 and GST- π expression levels

Compared to controls, miR-133b transfection decreased the mRNA expression levels of MDR1 and GST- π in all four cell lines, while anti-miR-133b transfection upregulated MDR1 and GST- π mRNA expression (Figure 4A, $P < 0.05$).

At the same time, protein expression levels of MDR1 and GST- π were also lower in miR-133b-transfected cells and were higher in Anti-miR-133b-transfected cells compared to controls (Figure 4B).

Discussion

This study investigated whether miR-133b contributes to the development of drug resistance in ovarian cancer. We showed that miR-133b expression was significantly lower in primary resistant ovarian carcinomas compared to the chemotherapy-sensitive carcinomas. In addition, miR-133b expression was lower in cisplatin-resistant and paclitaxel-resistant ovarian cancer cell lines compared to the chemotherapy-sensitive cells. Moreover, after miR-133b transfection, all examined cell lines showed an increased sensitivity to paclitaxel and cisplatin, while anti-miR-133b transfection decreased sensitivity to paclitaxel and cisplatin.

Figure 2 (Continued)

Figure 2 MiR-133b transfection increases the sensitivity of ovarian carcinoma cell lines to chemotherapy drugs.

Notes: Cell viability after 48 hours of the A2780, A2780/DDP, A2780/Taxol, and OVCAR3 cells transfected with a scrambled miRNA sequence (miR-C) or miR-133b, and scrambled anti-miR-133b (Anti-C) or anti-miR-133b. Cells were treated with increasing doses of (A) cisplatin (0, 37.5, 150, 600, 2,400, and 9,600 ng/mL) or (B) paclitaxel (0, 6.25, 25, 100, 400, and 1,600 ng/mL). Results are representative of three separate experiments; data are expressed as the mean $\pm$ standard deviation; * P < 0.05 compared with miR-C or Anti-C group.

Abbreviation: h, hours.

Together, these results suggest that miR-133b expression is important for chemotherapy drug sensitivity.

The role of miRNAs in the development of chemotherapy drug resistance in ovarian tumors has recently attracted attention. For example, van Jaarsveld et al reported that miR-141 induces cisplatin resistance by directly targeting the Kelch-Like ECH-Associated Protein 1 gene,¹⁸ while miR-21-3p induces cisplatin resistance in ovarian tumors by targeting the neuron navigator 3 gene.¹⁹ On the other hand, overexpression of some miRNAs will improve drug sensitivity rather than induce drug resistance. In particular, He et al reported that miR-152 sensitizes ovarian cancer cells to cisplatin,²⁰ while Zhou et al reported that miR-449a enhances cisplatin-induced cytotoxicity in ovarian cancer cells by decreasing NOTCH1

expression.²¹ Thus different miRNAs may have different functions in A2780 cells through targeting different genes.

We predicted that GST- π was a direct target of miR-133b. Moreover, we confirmed that miR-133b could target GST- π expression using a dual-luciferase reporter assay. GSTs are associated with the detoxification of cytostatic drugs, and previous studies indicate that GST polymorphisms may affect drug metabolism and influence chemotherapy and cancer survival.^{22,23} For example, Beeghly et al showed that reduced GST function may improve ovarian cancer survival after post-operative chemotherapy and that evaluating GST functional polymorphisms may help to predict ovarian cancer prognosis.²⁴ Indeed, many drug-resistant cancers express high levels of the π isoform of GST. Therefore, as increased miR-133b expression

Figure 3 Predicted binding region and transcriptional effects of miR-133b on its target gene, GST- π .

Notes: (A) The predicted seed region of miR-133b (hsa-miRNA-133b) in the 3'-UTR of GST- π (GST-P1) determined using a miRNA target program (<http://www.microrna.org>). (B) Effect of miR-133b on GST- π promoter activity using a Mutant and a Wild-GST- π . Luciferase activity (gene promoter activity) is unchanged when using a scrambled miRNA (miR-C) sequence or miR-133b with the Mutant. However, when the Wild-GST- π is used, the promoter activity is significantly reduced by miR-133b compared to miR-C. Each reporter plasmid was transfected at least three times, and each sample was assayed in triplicate; data are expressed as the mean $\pm$ standard deviation; * $P < 0.05$.

Abbreviations: 3'-UTR, 3'-untranslated region; Mutant, mutant 3'-UTR of GST- π ; Wild-GST- π , wild-type 3'-UTR of GST- π ; GST, glutathione S-transferase.

can reduce GST- π expression, it may prevent development of drug resistance and improve ovarian cancer prognosis. Our results showed that miR-133b transfection decreased GST- π expression at both the mRNA and protein level, and therefore may reduce chemotherapy drug resistance.

Drug resistance of tumor cells involves several mechanisms. For example, another important protein involved in drug resistance is MDR1. MDR1, also known as the P-glycoprotein 1 or the ATP-binding cassette subfamily B member 1, is important for transporting drugs across the cell membrane. Increased MDR1 expression can enhance drug resistance as the protein pumps drugs out of the cells and decreases the intracellular drug concentration.²⁵⁻³⁰ In our study, miR-133b transfection decreased MDR1 expression at both mRNA and protein levels.

Therefore, we demonstrated that overexpression of miR-133b increases ovarian cancer cell sensitivity to

cisplatin and paclitaxel by decreasing GST- π and MDR1 expression. We suggest that the combination of miR 133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers. However, the precise molecular mechanisms of miR-133b, and the opportunities for its clinical manipulation, require further investigation.

Conclusion

In summary, we demonstrated that overexpression of miR-133b increases ovarian cancer cell sensitivity to cisplatin and paclitaxel by decreasing GST- π and MDR1 expression. We suggest that the combination of miR-133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers. However, the precise molecular mechanisms of miR-133b, and the opportunities for its clinical manipulation, require further investigation.

Figure 4 miR-133b downregulates GST- π , MDR1 mRNA, and protein expression levels.

Notes: (A) Comparison of GST- π and MDR1 mRNA levels relative to 18S mRNA levels in the A2780, A2780/DDP, A2780/Taxol, and OVCAR3 cells alone (untreated); or transfected with a scrambled miRNA sequence (miR-C) or miR-133b, or anti-miR-133b or scrambled anti-miRNA sequence (Anti-C), determined by reverse transcription polymerase chain reaction. Results are representative of three separate experiments; data are expressed as the mean $\pm$ standard deviation; * $P < 0.05$. (B) Comparison of GST- π and MDR1 protein levels in A2780, A2780/DDP, A2780/Taxol, and OVCAR3 cells alone (untreated); or transfected with a scrambled miRNA sequence (miR-C) or miR-133b, or anti-miR-133b or scrambled anti-miRNA sequence (Anti-C), determined by Western blotting. GAPDH expression is used as a control.

Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GST, glutathione S-transferase; MDR, multidrug resistance 1.

Acknowledgments

This work was supported by the Liaoning Science and Technology Grant (2013021077) and the Natural Scientific Foundation of China (81202049, 81472400, and 81472502).

Author contributions

YZ, SC, JWJ, KXS and ZHZ conceived the study, carried out the acquisition, analysis, and interpretation of data, and took part in drafting/revising the article. All authors read

and approved the final manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosure

The authors report no conflicts of interest in this work.

References

- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin*. 2009;59(4):225–249.
- Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. *Obstet Gynecol*. 2015;126(3):491–497.
- Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK. Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. *Indian J Cancer*. 2006;43(1):16–19.
- Allegra A, Alonci A, Campo S, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). *Int J Oncol*. 2012;41(6):1897–1912.
- Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. *Pharmacol Ther*. 2011;131:18–32.
- Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature*. 2010;466:835–840.
- Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. *Nat Rev Drug Discov*. 2010;9:775–789.
- Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. *Nat Rev Cancer*. 2006;6:259–269.
- Babu JM, Prathibha R, Jijith VS, Hariharan R, Pillai MR. A miR-centric view of head and neck cancers. *Biochim Biophys Acta*. 2011;1816(1):67–72.
- To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. *Mol Cell Biol*. 2008;28(17):5147–5161.
- Li Z, Hu S, Wang J, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. *Gynecol Oncol*. 2010;119:125–130.
- Li H, Xu H, Shen H, Li H. microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. *Oncol Lett*. 2014;7(1):183–188.
- Ma MT, He M, Wang Y, et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). *Cancer Lett*. 2013;339(1):107–115.
- Guo L, Bai H, Zou D, et al. The role of microRNA-133b and its target gene FSCN1 in gastric cancer. *J Exp Clin Cancer Res*. 2014;33:99.
- Chen XN, Wang KF, Xu ZQ, et al. MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. *Cancer Cell Int*. 2014;14:70.
- Lin CW, Li XR, Zhang Y, et al. TAp63 suppress metastasis via miR-133b in colon cancer cells. *Br J Cancer*. 2014;110(9):2310–2320.
- Qin W, Dong P, Ma C, et al. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. *Oncogene*. 2012;31(36):4067–4075.
- van Jaarsveld MT, Helleman J, Boersma AW, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. *Oncogene*. 2013;32(36):4284–4293.
- Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. *Gynecol Oncol*. 2015;137(1):143–151.
- He J, Yu JJ, Xu Q, et al. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. *Autophagy*. 2015;11(2):373–384.
- Zhou Y, Chen Q, Qin R, Zhang K, Li H. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells. *Tumour Biol*. 2014;35(12):12369–12378.
- Popęda M, Pluciennik E, Bednarek AK. [Proteins in cancer multidrug resistance]. *Postępy Hig Med Dosw (Online)*. 2014;68:616–632. Polish.
- Schnekenburger M, Karius T, Diederich M. Regulation of epigenetic traits of the glutathione S-transferase P1 gene: from detoxification toward cancer prevention and diagnosis. *Front Pharmacol*. 2014;5:170.
- Beeghly A, Katsaros D, Chen H, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. *Gynecol Oncol*. 2006;100(2):330–337.
- Zhang T, Guan M, Jin HY, Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. *Gynecol Oncol*. 2005;97:501–507.
- Chen J, Ding Z, Peng Y, et al. HIF-1 α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. *PLoS One*. 2014;9(6):e98882.
- Andorfer P, Rotheneder H. Regulation of the MDR1 promoter by E2F1 and EAP. *FEBS Lett*. 2013;587:1504–1509.
- Wang Q, Wang Z, Chu L, et al. The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines. *PLoS One*. 2015;10(5):e0125473.
- Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. *Biomed Res Int*. 2013;2013:241763.
- Xing AY, Shi DB, Liu W, et al. Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. *Exp Mol Pathol*. 2013;94:481–485.

Supplementary materials

Table S1 Primers for reverse transcription polymerase chain reaction

Gene	Primer sequence	Annealing temperature (°C)	Product size (bp)	Extension time (seconds)
<i>GST-π</i>	F: 5'-TTTCGCCGCCGAGTCT-3' R: 5'-TCCACGGTCACCACCTCCTC-3'	60	135	34
<i>MDR1</i>	F: 5'-AGGCTATCATTACTCTTTACC-3' R: 5'-TCTGGCTTCCGTTGC-3'	60	161	34
<i>miR-133b</i>	F: 5'-CCTCAGAAGAAAGATGCC-3' R: 5'-GCTGGTTGAAGGGGAC-3'	60	85	34
<i>18S</i>	F: 5'-ACGGACAGGATTGACAGATT-3' R: 5'-GGCGTAGGGTAGGCACA-3'	60	288	34

Table S2 Comparative cell viability result

Cisplatin (ng/mL)	0	37.5	150	600	2,400	9,600
A2780						
Untreated	1	0.9888	0.9124	0.5321	0.1901	0.0911
miR-C	1	0.9870	0.9230	0.5670	0.1700	0.0807
miR-133b	1	0.8978	0.6791	0.3747	0.1414	0.0114
Anti-C	1	0.9687	0.9023	0.5467	0.1710	0.0812
Anti-miR-133b	1	1.1375	1.0291	0.6687	0.2645	0.1625
A2780/Taxol						
Untreated	1	0.9512	0.8930	0.7392	0.2390	0.1678
miR-C	1	0.9850	0.9138	0.7453	0.2436	0.1973
miR-133b	1	0.8838	0.7597	0.5607	0.1620	0.0701
Anti-C	1	0.9038	0.8760	0.6902	0.2436	0.1973
Anti-miR-133b	1	1.0389	0.9736	0.8559	0.3623	0.2236
A2780/DDP						
Untreated	1	0.9798	0.9344	0.8533	0.5512	0.0666
miR-C	1	0.9775	0.9842	0.8479	0.5891	0.0935
miR-133b	1	0.9349	0.8157	0.6748	0.4039	0.0534
Anti-C	1	0.9491	0.9570	0.8492	0.5910	0.0543
Anti-miR-133b	1	0.9842	1.1026	1.0899	0.7376	0.0915
OVCAR3						
Untreated	1	0.8269	0.6313	0.4059	0.1387	0.1360
miR-C	1	0.8024	0.6137	0.4370	0.1392	0.1453
miR-133b	1	0.6518	0.4720	0.2361	0.1038	0.1016
Anti-C	1	0.8024	0.6124	0.4357	0.1423	0.1430
Anti-miR-133b	1	0.9473	0.7267	0.5712	0.2828	0.2097
Paclitaxel (ng/mL)						
	0	6.25	25	100	400	1,600
A2780						
Untreated	1	0.3446	0.2263	0.1647	0.1698	0.1354
miR-C	1	0.3670	0.2344	0.1756	0.1701	0.1481
miR-133b	1	0.2652	0.1348	0.1044	0.1041	0.0912
Anti-C	1	0.3267	0.2134	0.1576	0.1470	0.1248
Anti-miR-133b	1	0.4507	0.2973	0.2313	0.2069	0.1730
A2780/Taxol						
Untreated	1	0.5472	0.5348	0.4954	0.4298	0.1996
miR-C	1	0.5599	0.5191	0.4745	0.4244	0.1973
miR-133b	1	0.5270	0.4398	0.3540	0.3051	0.1523
Anti-C	1	0.5060	0.5112	0.4575	0.4024	0.1797
Anti-miR-133b	1	0.6459	0.5975	0.5588	0.4864	0.4415

(Continued)

Table S2 (Continued)

Paclitaxel (ng/mL)	0	6.25	25	100	400	1,600
A2780/DDP						
Untreated	I	0.9153	0.7517	0.6538	0.6006	0.4989
miR-C	I	0.9349	0.7644	0.6769	0.6241	0.5400
miR-133b	I	0.8895	0.6712	0.5906	0.5382	0.4586
Anti-C	I	0.9391	0.7346	0.6848	0.5891	0.5343
Anti-miR-133b	I	0.9570	0.9367	0.8479	0.7597	0.6279
OVCAR3						
Untreated	I	0.3430	0.2667	0.2569	0.2509	0.1239
miR-C	I	0.3629	0.2566	0.2586	0.2281	0.1374
miR-133b	I	0.2936	0.2036	0.1759	0.1382	0.0739
Anti-C	I	0.2947	0.2570	0.2558	0.2284	0.1739
Anti-miR-133b	I	0.3966	0.3721	0.3297	0.2975	0.2345

Drug Design, Development and Therapy**Dovepress****Publish your work in this journal**

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>